GET DAILY SIGNALSReplimune Group (REPL) Stock Advances +48% Following TUDRIQEV Launch
Key Takeaways
- Replimune Group (REPL) shares have advanced roughly 48% over the trailing 30 days, rising from about $13.07 to near $19.40.
- The rally is anchored to the commercial launch of TUDRIQEV, the company's first FDA-approved therapy, which reached its first patients in early October 2026.
- Fiscal second-quarter 2027 results, reported in late October, showed a narrower net loss and a stronger cash position, prompting several analysts to raise their price targets.
- Over the last quarter, the stock has climbed approximately 63%, building on the August 2026 FDA accelerated approval.
- Key catalysts ahead include launch execution, the IGNYTE-3 confirmatory trial, and progress from the RP2 clinical program.
Company Background and Market Position
Replimune Group, Inc. is a Woburn, Massachusetts-based biotechnology company founded in 2015 to develop novel oncolytic immunotherapies for cancer. Its proprietary RPx platform is built on a modified herpes simplex virus type 1 (HSV-1) backbone engineered to kill tumor cells directly while stimulating a systemic anti-tumor immune response.
The company's lead product, TUDRIQEV (vusolimogene oderparepvec-wtpg, formerly RP1), received U.S. FDA accelerated approval in August 2026 for use in combination with Bristol Myers Squibb's nivolumab (BMY) to treat adults with unresectable advanced cutaneous melanoma that has progressed after an anti-PD-1-based regimen. As Replimune's first marketed product, TUDRIQEV represents the core of its near-term commercial opportunity, with a confirmatory Phase 3 trial (IGNYTE-3) and an earlier-stage candidate, RP2, expanding the pipeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, REPL shares have risen roughly 48%, from a closing level near $13.07 to approximately $19.40. The sharpest single-day advance came in late October, when the stock jumped more than 20% following the company's fiscal second-quarter report and positive early launch commentary.
Over the last quarter, the gain is even more pronounced. From a level near $11.91 in early August, the stock has climbed about 63%, reflecting the market's re-rating of the company from a development-stage biotech to a commercial-stage oncology franchise. While the quarterly trend has been broadly positive, it has also been volatile, with periodic pullbacks tied to launch-scaling questions and broader biotech sector sentiment. From what I see, the move aligns with the shift toward commercial execution.
Factors Behind the Recent 30-Day Rally
The dominant catalyst over the past month has been the commercial launch of TUDRIQEV. The company reported that the therapy was first delivered to patients with advanced melanoma on October 6, with more than 15 institutions prescribing the product early in the launch. Management described strong early demand from melanoma treaters and rapid integration of the therapy into clinical practice.
The October 28 fiscal second-quarter 2027 report reinforced the positive tone. Replimune posted a net loss of $57.1 million, or $0.54 per share, narrowing from $83.1 million a year earlier, while research and development and selling expenses both declined. The company ended the quarter with $307.8 million in cash and cash equivalents, supported in part by a $141 million equity offering completed in August, and said the balance sheet funds operations for more than 12 months.
Analysts responded by lifting targets, with Leerink Partners raising its price target to $31 and Jefferies to $29, while maintaining positive ratings. The average consensus rating remained Buy. Elevated short interest also added fuel to the move: short interest as a percentage of float climbed to a one-month high near 34% following the earnings-driven spike, creating conditions for a potential squeeze. I’m watching this closely as short interest levels can amplify moves in either direction.
Drivers of Performance Over the Last Quarter
The multi-month rally reflects the resolution of a long and contentious regulatory process. TUDRIQEV's path to market included two FDA Complete Response Letters, in July 2025 and April 2026, before a 10-3 advisory committee vote in late July 2026 and final accelerated approval in early August. The approval transformed Replimune from a pre-revenue company facing significant regulatory uncertainty into one with a marketed oncology product.
Since approval, investor focus has shifted from binary regulatory risk to commercial execution. Positive early launch indicators, a strengthening cash position, and constructive analyst commentary have supported the stock's re-rating through the quarter, even as broader volatility and lingering legal matters — including a securities class action related to earlier regulatory disclosures — remain in the background.
Key Catalysts Ahead for Investors
Looking ahead, the most important variable is TUDRIQEV launch execution — specifically the pace of new accounts, patient starts, formulary access, and revenue recognition, which is expected to begin in the fiscal third quarter given that first shipments occurred in early October. Continued approval of TUDRIQEV is contingent on the confirmatory IGNYTE-3 Phase 3 trial, making enrollment progress and eventual efficacy data critical longer-term milestones.
Investors should also monitor progress from the RP2 program in metastatic uveal melanoma, the company's cash runway and any future financing needs, competitive dynamics in the post-PD-1 melanoma setting, and the status of outstanding securities litigation. As with any clinical-stage-to-commercial transition, the gap between early prescriber enthusiasm and sustained commercial revenue will be a key test of the stock's recent gains.
Exploring Tickeron’s AI Trading Bots for Systematic Strategies
In my own research process, I often turn to Tickeron’s AI Trading Bots to evaluate automated approaches that complement fundamental analysis. The platform offers a range of strategies across different timeframes and market conditions, allowing users to review performance metrics and see how these tools have performed on names like REPL. This can provide an additional data layer when assessing volatility and potential entry points without replacing core due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
REPL in upward trend: 10-day moving average moved above 50-day moving average on November 02, 2026
The 10-day moving average for REPL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on REPL as a result. In 67 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for REPL just turned positive on October 26, 2026. Looking at past instances where REPL's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.
REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 185 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REPL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.382) is normal, around the industry mean (3.104). P/E Ratio (-6.187) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of oncolytic immunotherapies
Industry Biotechnology
Advertisement